Roche medical director could face GMC if the company withheld relevant data on oseltamivirBMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8408 (Published 11 December 2012) Cite this as: BMJ 2012;345:e8408
- Zosia Kmietowicz
The chairman of the UK National Institute for Health and Clinical Excellence has said that if Roche were found to have withheld relevant data on its drug oseltamivir (Tamiflu) the company’s medical director at the time of the submission to NICE could be reported to the General Medical Council.
Michael Rawlins was responding to a letter from the BMJ’s editor in chief, Fiona Godlee, in which she asked NICE to withdraw its guidance on oseltamivir until it “has received and reviewed the full clinical trial data.” The request was the latest move in the BMJ’s open data campaign (bmj.com/tamiflu), which aims to persuade Roche to honour the promise it made almost three years ago to make key trial data on oseltamivir available for independent scrutiny.
In her letter Godlee said that …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial